Skip to content

Biohaven BHVN Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding

Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding at other companies

Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$0
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$0
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$0
ADMA Biologics logo
ADMA BiologicsADMA
$0
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$0
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Biohaven's preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding?
Biohaven (BHVN) reported preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding of $0 in Q1 2026.
What does preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding mean?
This represents the par value of preferred shares issued by the company, which carry specific rights and preferences over common stock, such as priority in dividend payments or liquidation. Preferred stock is a form of hybrid capital that sits between debt and common equity. If no shares are issued, this value remains at zero.